日本語 
Zealand Pharma and Generate Biomedicines have entered a collaboration to develop AI‑engineered protein therapeutics for obesity and other metabolic diseases. The collaboration was announced on October 13 2026. It brings together Zealand Pharma’s expertise in metabolic health and Generate Biomedicines’ artificial intelligence platform, which links computer‑based protein design with fast large‑scale experimental testing.
The partnership will start with two programs and the partners may add a later. They want to create protein therapeutics that can act on several biological targets at once. This could help treat disease pathways with one medicine. The protein candidates are still in research and development. The announcement does not prove that they will be safe or effective in patients.
AI and Experimental Research to Guide Protein Design
Generate Biomedicines will use its Generate Platform to steer research and select lead candidates. This platform mixes AI with laboratory experiments letting computer‑designed proteins be tested and improved with real data.
First the partners will set the qualities that a medicine should have for each of the two initial programs. After that Generate will use its platform and lab tools to design protein candidates that fit those requirements.
This method shows a growing trend in biotechnology where AI helps design proteins that perform biological jobs. Of depending only on old discovery methods scientists can use computer models to create candidate designs and then test them in the lab.
Ai‑generated designs still need careful lab testing and later preclinical and clinical studies. The technology does not promise that a candidate will become a medicine.
For Zealand Pharma this agreement widens its development beyond its usual focus, on peptide‑based medicines and small molecules. Adding engineered proteins could give another way to study the mechanisms that drive obesity and related metabolic conditions.
Zealand Pharma to Lead Clinical Development and Commercialization
The companies have split duties based on what they do. Generate will run the discovery research. Pick the main candidates while Zealand Pharma will handle the later clinical development submit to regulators and sell the products around the world.
This setup gives Generate a job in the early research part and puts the later development and possible sales on Zealand Pharma. The split also means that how far things go will hinge on picking the candidates and on the later development.
The partnership focuses on obesity and other metabolic diseases which’re fields that attract big pharmaceutical investment. The companies are looking at treatments that might hit biological pathways and could give new or extra options compared to current medicines.
The planned multispecific proteins aim to touch than one biological target. Whether this method will give help to patients rests on the qualities of each candidate and the proof gathered during development.
Neither Generate nor Zealand Pharma has shared results for the new collaboration’s candidates and no approval or launch schedule has been given.
Agreement Includes Upfront Payment and Potential Milestones of $1.2 Billion
Under the agreement Generate will get an upfront payment of $30 million and could earn as much as $35 million in early preclinical milestone payments for the two first programs.
The agreement also lets Generate collect milestone payments that could reach about $1.2 billion. These include development, regulatory and commercial milestones, plus tiered royalties on future worldwide net sales of products that are sold under the partnership.
These numbers show payments that depend on development and commercial results, not on guaranteed money. The real amount paid will depend on whether the set milestonesre met and whether any medicines reach the market.
The agreement also has an option to add a program giving the companies a chance to keep working beyond the first two candidates.
For Generate this partnership lets the company use its AI protein engineering platform on a bigger metabolic disease set. For Zealand Pharma it gives access to another technology platform without needing the company to build every part of the protein-design skill, on its own.
Enabled Drug Development Faces Clinical and Regulatory Hurdles
This partnership shows how drug companies are mixing computer-based research with traditional drug development methods. AI can help create and pick out drug molecules but human clinical trials are still needed to see if those molecules are safe and work well in people.
Also Read: Zeal Launches MEDSCOPE for OTC Pharma Data Analysis
Protein-based drugs also need checking. That includes how active they are biologically how they’re made possible side effects and whether they fit certain groups of patients. Every candidate must go through the steps in development and meet regulatory rules before it can be sold.
So this deal is about starting research early. Not, about adding a new obesity treatment right away. How much it helps in the run will depend on which candidates are chosen, what the later studies show and whether both companies can move the projects forward.
By using AI hands-on protein engineering and Zealand Pharma’s deep knowledge of metabolic diseases the team hopes to find new ways to study obesity and other metabolic problems. The big next steps will be. Testing potential protein candidates and seeing what results come from moving the projects forward.
English